FDA Approves Merck’s RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults
Dateline City:
WHITEHOUSE STATION, N.J.
RAGWITEK is the First and Only FDA Approved Sublingual Allergen Immunotherapy Tablet Indicated for the Treatment of Short Ragweed Pollen Allergies
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for
Sublingual Use (12 Amb a 1-U).
Language:
English
Contact:
MerckMedia Contacts:Pamela Eisele, 267-305-3558Robert Consalvo, 908-423-6595orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Prescription Medicine News Corporate News Latest News Source Type: news
More News: Allergy | Allergy & Immunology | Conjunctivitis | Food and Drug Administration (FDA) | Hay Fever | Merck | Pharmaceuticals